about the author

Kyle Blankenship

kyle@endpointsnews.com @ka_blankenship
Kyle Blankenship on LinkedIn

author articles

Long­time Zymeworks CEO, co-founder Tehrani hits the ex­it in fa­vor of se­r­i­al biotech en­tre­pre­neur

4 years ago
People

Spec­trum hits the re­set but­ton, slic­ing away 30% of its work­force in piv­ot around 2 lead as­sets

4 years ago
People
R&D

Al­lakos drops a pair of duds on pa­tient-re­port­ed symp­tom re­lief for GI dis­ease, va­por­iz­ing bil­lions off its val­ue

4 years ago
R&D

FDA slams clin­i­cal hold on tiny psy­che­delics play­er's shot at bring­ing LSD-as­sist­ed ther­a­py to more pa­tients

4 years ago
R&D
FDA+

Third Rock­'s Am­bys clos­es a megaround with the clin­ic still a ways off for its re­gen­er­a­tive cells for liv­er dis­ease

4 years ago
Financing

Roche, Genen­tech tap re­gen­er­a­tive cell ther­a­py play­er for drug col­lab­o­ra­tion in eye dis­ease

4 years ago
R&D

Weeks af­ter earn­ing CEO's stamp of ap­proval, a No­var­tis skin drug los­es head-to-head bat­tle with stan­dard of care

4 years ago
R&D
Pharma

Omega Funds goes back to the well with newest $650M fund, tak­ing a 'stage-ag­nos­tic' ap­proach to biotech VC

4 years ago
Financing

Buoyed by semaglu­tide suc­cess, No­vo Nordisk un­corks plans for $2.58B man­u­fac­tur­ing ex­pan­sion in Den­mark

4 years ago
Manufacturing

Days af­ter buy­out news, Vi­for out­lines plan to of­fload 'non-core' fin­ished drug man­u­fac­tur­ing wing

4 years ago
R&D
Manufacturing

Pfiz­er opens doors at newest gene ther­a­py site in NC as part of $800M push in­to next-gen drugs

4 years ago
Cell/Gene Tx
Manufacturing

IN8bio's 'off-the-shelf' gam­ma delta T cells stave off re­lapse for high-risk leukemia pa­tients in very ear­ly da­ta cut

4 years ago
R&D
Cell/Gene Tx

#JPM22 goes vir­tu­al, cav­ing to pres­sure af­ter a wave of big drug­mak­ers pull out due to Omi­cron fears

4 years ago
Pharma

ASH: Roche's an­ti­body-drug con­ju­gate Po­livy added to chemo-an­ti­body com­bo boosts sur­vival in ear­ly-stage lym­phoma

4 years ago
R&D

ASH: Sanofi un­corks late-stage da­ta for RNAi drug fi­tusir­an in he­mo­phil­ia, with all eyes on safe­ty pro­file

4 years ago
R&D
Cell/Gene Tx

ASH: No­var­tis rolls out ear­ly da­ta for a pair of 'sec­ond-gen' CAR-Ts with more pro­duc­tive cells de­liv­ered faster

4 years ago
R&D
Cell/Gene Tx

ASH: Gilead­'s CAR-T Yescar­ta holds up in more first-line lym­phoma pa­tients as part of ear­li­er use push

4 years ago
R&D
Cell/Gene Tx

ASH: An­oth­er 'off-the-shelf' cell ther­a­py leader shows dura­bil­i­ty is­sues, rais­ing re­newed con­cerns about emerg­ing ...

4 years ago
R&D
Cell/Gene Tx

Op-ed: What we’re watch­ing close­ly as an un­usu­al #ASH21 kicks off in At­lanta

4 years ago
R&D

ASH: Roche un­corks eye­pop­ping re­spons­es in bis­pe­cif­ic test, hop­ing to add a jew­el to its fu­ture port­fo­lio

4 years ago
R&D

ASH: Gilead­'s Kite un­veils more da­ta on Yescar­ta's win in sec­ond-line lym­phoma pa­tients, set­ting up bat­tle for SOC

4 years ago
R&D
Cell/Gene Tx

ASH: With Yescar­ta lead­ing in ear­li­er-line lym­phoma, Bris­tol My­ers keeps the heat on with full da­ta for Breyanzi

4 years ago
R&D
Cell/Gene Tx

New­path Part­ners kicks off $350M fund with a wun­derkind hold­ing the bag and an all-star sci­en­tif­ic team wait­ing in ...

4 years ago
Financing
Startups

Aca­dia touts late-stage win for its Rett syn­drome drug, edg­ing out a lead against its com­peti­tors

4 years ago
R&D
First page Previous page 123456 Next page Last page
A service from the Financial Times